RXRX Stock Overview
Operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Recursion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.15 |
| 52 Week High | US$16.75 |
| 52 Week Low | US$4.97 |
| Beta | 0.86 |
| 11 Month Change | -3.79% |
| 3 Month Change | -12.77% |
| 1 Year Change | 18.68% |
| 33 Year Change | -73.71% |
| 5 Year Change | n/a |
| Change since IPO | -70.77% |
Recent News & Updates
Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Recent updates
Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21Shareholder Returns
| RXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.1% | -1.3% | 0.4% |
| 1Y | 18.7% | 7.7% | 22.9% |
Return vs Industry: RXRX exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: RXRX underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| RXRX volatility | |
|---|---|
| RXRX Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RXRX has not had significant price volatility in the past 3 months.
Volatility Over Time: RXRX's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 500 | Chris Gibson | www.recursion.com |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.
Recursion Pharmaceuticals, Inc. Fundamentals Summary
| RXRX fundamental statistics | |
|---|---|
| Market cap | US$2.31b |
| Earnings (TTM) | -US$354.11m |
| Revenue (TTM) | US$46.24m |
47.0x
P/S Ratio-6.1x
P/E RatioIs RXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXRX income statement (TTM) | |
|---|---|
| Revenue | US$46.24m |
| Cost of Revenue | US$62.19m |
| Gross Profit | -US$15.95m |
| Other Expenses | US$338.16m |
| Earnings | -US$354.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | -34.50% |
| Net Profit Margin | -765.90% |
| Debt/Equity Ratio | 0.3% |
How did RXRX perform over the long term?
See historical performance and comparison